Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

AquaVita NextGen vs SkinnyRx

By GLP-1 ScorecardUpdated

Our take

SkinnyRx advertises a lower first-month injection price. AquaVita makes it easier to compare the listed cost of one supply with a three-month purchase.

Ask SkinnyRx what the second charge will be

The SkinnyRx review separates its $99 first-month injection offer from the still-unconfirmed recurring price and explains when to cancel before renewal processing.

Read the SkinnyRx review →

A first-month offer does not establish the total for three months. Confirm the prescription, usable supply and cancellation deadline.

AquaVita NextGenFactor scores not reassessed.
Site position #447

Lower score

SkinnyRx
Site position #274

Higher score

Score comparison

SkinnyRx has the higher recorded score — 60.5/100 to 56.3/100.

SkinnyRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Publishes four introductory compounded-treatment offers, but continuing costs, usable supply and the interaction between cancellation and refund rules need confirmation.

Before you choose

Before comparing the headline prices, the AquaVita NextGen review and the SkinnyRx review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.

If neither one fits, AquaVita NextGen vs TeleCareSpot and CoreAge Rx vs SkinnyRx compare each of them with another graded program, and the list of alternatives to AquaVita NextGen ranks the programs closest to AquaVita NextGen on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueSkinnyRx +29
23
52
Dose & formulationSkinnyRx +13
75
88
Clinical oversightAquaVita NextGen +27
82
55
Labs & monitoringAquaVita NextGen +13
53
40
FulfillmentSkinnyRx +20
62
82
Contract termsAquaVita NextGen +9
47
38
AquaVita NextGen · top barSkinnyRx · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricAquaVita NextGenSkinnyRx
WeighScore56.3/10060.5/100
GradeCC
Site position#447#274
Semaglutide$215 for one month or $600 for three months; confirm totalInjection advertised $99 first month; compounded tablets $149 first month. Confirm the recurring price, selected term and usable prescription supply.
Tirzepatide$320 for one month or $900 for three months; confirm totalInjection advertised $99 first month; compounded dissolving tablets $199 first month. Confirm the recurring price, selected term and usable prescription supply.
Coverage5 states listedCurrent terms exclude certain compounded offerings in Alabama, Louisiana and Mississippi; confirm eligibility for the exact route and pharmacy.
Brand-name accessNot confirmedNot confirmed
Oral / sublingualNot confirmedYes
AquaVita NextGen

Site position #447 · C

Factor scores not reassessed.

Strengths

  • Public catalog lists one- and three-month purchase prices separately
  • Publishes a separate process for shipping or delivery issues

What to consider

  • Confirm the selected prescription, pharmacy and full charge
  • Public terms do not clearly say what happens to the payment after clinical rejection
SkinnyRx

Site position #274 · C

FDAWarning letter issued to Lean Rx, Inc. dba SkinnyRx in February 2026. See the FDA warning-letter database.

Strengths

  • Advertises separate first-month prices for both compounded molecules and both injection and tablet routes
  • Current terms describe the ninety-day commercial guarantee’s dose logging, claim-window, promotional eligibility and coverage requirements
  • Names a medical director/advisor in public information; this does not identify the assigned treating professional
  • Publishes compounded-treatment state exclusions and cancellation channels rather than leaving every operational detail unspecified

What to consider

  • First-month prices do not establish the recurring amount, selected full prepayment or usable medication quantity
  • Cancellation requires five days’ notice before renewal processing, which can itself precede the next subscription period
  • The guarantee’s bundled-refund language needs clarification alongside general third-party-fee deductions, medication-return requirements and product FAQ restrictions
  • Microdose badges and daily tablet descriptions do not establish a separate price, complete prescription or equivalent branded-treatment results
  • The actual prescribing practice, assigned clinician, dispensing pharmacy, physical compounder and patient-lab costs remain unconfirmed
  • The named advisor’s Florida record flags discipline and a public complaint, while Oregon lists a surrendered license; neither record determines every clinician’s authority or the patient assignment
  • FDA issued Lean Rx Inc. dba SkinnyRx a warning letter on February 20, 2026; website testing claims do not establish independent pharmacy verification.

Featured provider

SkinnyRx

SkinnyRx scores 60.5/100 (C). Publishes four introductory compounded-treatment offers, but continuing costs, usable supply and the interaction between cancellation and refund rules need confirmation.

Commercial relationships affect this placement. The score comparison above is separate.

FDAWarning letter issued to Lean Rx, Inc. dba SkinnyRx in February 2026. See the FDA warning-letter database.

Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.

← Back to the scorecard